Use of polylactic acid and copolymer thereof for promoting growth of bone tissue and cartilage tissue

MYPI2026000136A0Undetermined Publication Date: 2025-01-12CHANGCHUN SINOBIOMATERIALS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026000136
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-12
Filing Date
2024-07-10
Publication Date
2025-01-12

AI Technical Summary

Technical Problem

No polylactic acid and its copolymers or microspheres thereof are used in the prior art to promote the growth of bone and cartilage tissues, and effective pharmaceutical forms are lacking for this purpose.

Method used

Using polylactic acid and its copolymers or their microspheres, microspheres are prepared by mixing with solvents, emulsifying and freeze-drying, and combining auxiliary materials and other active ingredients to form drugs for promoting the growth of bone and cartilage tissues. The administration method includes Intravenous injection, in situ injection, etc.

Benefits of technology

Polylactic acid and its copolymer microspheres significantly promote the growth of bone and cartilage tissues, providing a new therapeutic approach to verify its effectiveness through proliferation experiments and histological testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2026000136_DRAWING_001
    Figure PI2026000136_DRAWING_001
  • Figure PI2026000136_DRAWING_002
    Figure PI2026000136_DRAWING_002
  • Figure PI2026000136_DRAWING_003
    Figure PI2026000136_DRAWING_003
Patent Text Reader

Abstract

The use of polylactic acid and a copolymer thereof or a microsphere thereof in the preparation of a drug for promoting the growth of bone tissue and cartilage tissue. The molecular weight of the polylactic acid and the copolymer thereof is 400 Da to 300 kDa. It is found for the first time that the polylactic acid and the copolymer thereof or the microsphere thereof have an effect of promoting the growth of bone tissue and cartilage tissue, thereby providing a new way for promoting the growth of bone tissue and cartilage tissue. Figure 3.
Need to check novelty before this filing date? Find Prior Art

Description

Application of polylactic acid and its copolymers in promoting the growth of bone tissue and cartilage tissue

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese patent application No. 202310853821.9, filed on July 12, 2023, entitled “Application of polylactic acid and its copolymers in promoting cartilage tissue growth”, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present invention relates to the technical field of polymer medical materials, in particular to the application of polylactic acid and its copolymers in promoting the growth of bone tissue and cartilage tissue. Background Art

[0004] The molecular formula of polylactic acid (PLA) is -[OCH(CH3)CO]-, which is mainly prepared by lactic acid polymerization or lactide ring-opening polymerization. Its structural formula is

[0005] PLA and its copolymers not only possess excellent mechanical strength and chemical stability, but also possess good biocompatibility and biodegradability. In recent years, extensive research has been conducted both domestically and internationally on their biomedical applications. They have found widespread application in surgical sutures, bone repair materials, controlled drug release systems, and tissue scaffolds (such as artificial bone and skin).

[0006] Among them, poly-L-lactic acid (trade name Sculptra™, Poly-L-lactic acid, PLLA) contains biodegradable, biocompatible synthetic polymer microparticles. In 2004, it was approved by the US FDA for use in filling sagging skin caused by facial fat atrophy in AIDS patients. In 2009, the US FDA officially approved poly-L-lactic acid fillers for improving nasolabial folds.

[0007] However, there is no report in the prior art as to whether polylactic acid, its copolymers or its microspheres can be used as polymer drugs to promote the growth of bone tissue and cartilage tissue.

[0008] Summary of the Invention

[0009] In view of the deficiencies in the prior art, the present invention provides the use of polylactic acid and its copolymers or their microspheres in the preparation of drugs for promoting the growth of bone tissue and cartilage tissue, which provides a new approach to promote the growth of bone tissue and cartilage tissue.

[0010] The present invention provides the use of polylactic acid and its copolymers, polylactic acid microspheres, and polylactic acid copolymer microspheres in the preparation of drugs for promoting the growth of bone tissue and cartilage tissue, wherein the molecular weight of the polylactic acid and its copolymers is 400Da-300kDa; preferably, the molecular weight of the polylactic acid and its copolymers is 5000Da-100kDa; for example, 5000Da-20kDa, 15000Da.

[0011] According to an embodiment of the present invention, the polylactic acid includes L-polylactic acid, D-polylactic acid, and racemic polylactic acid; preferably L-polylactic acid.

[0012] According to an embodiment of the present invention, the polylactic acid copolymer includes one or more of polylactic acid glycolic acid copolymer, polylactic acid polyethylene glycol copolymer, polyethylene glycol polylactic acid glycolic acid copolymer, polylactic acid-chitosan copolymer, and lactide-caprolactone copolymer; preferably, the polylactic acid copolymer is polylactic acid glycolic acid copolymer.

[0013] According to an embodiment of the present invention, the preparation method of polylactic acid microspheres and polylactic acid copolymer microspheres comprises the following steps:

[0014] 1) mixing polylactic acid or a polylactic acid copolymer and a solvent to obtain a polylactic acid solution or a polylactic acid copolymer solution;

[0015] Preferably, the solvent is any one of dichloromethane, chloroform, ethyl acetate, acetone or toluene, or a mixture of any two or more thereof;

[0016] 2) mixing the polylactic acid solution or the polylactic acid copolymer solution with the polyvinyl alcohol aqueous solution, emulsifying at high speed, stirring to remove the solvent, and freeze-drying to obtain polylactic acid microspheres.

[0017] According to an embodiment of the present invention, in step 1), the mass volume ratio of polylactic acid or polylactic acid copolymer to solvent is 1g:5mL-1g:30mL, preferably 1g:10mL-1g:20mL, for example 1g:15mL;

[0018] and / or, in step 2), the mass concentration of the polyvinyl alcohol aqueous solution is 0.05%-5.0%, preferably 0.1%-2.0%, for example 0.5%;

[0019] and / or, in step 2), the volume ratio of the polylactic acid solution or polylactic acid copolymer solution to the polyvinyl alcohol aqueous solution is 1:5-1:30, preferably 1:10-1:20, for example 1:13, 1:15;

[0020] and / or, in step 2), the rotation speed of the high-speed emulsification is 1000 rpm / min-5000 rpm / min, for example, 3000 rpm / min;

[0021] And / or, in step 2), the emulsification time is 5-20 minutes, for example 10 minutes.

[0022] According to an embodiment of the present invention, during administration, the mass concentration of polylactic acid and its copolymers, polylactic acid microspheres, and polylactic acid copolymer microspheres is 1%-60%, preferably 5%-50%, for example 10%, 20%, 30%, or 40%.

[0023] For example, a solution with the above mass concentration is prepared.

[0024] According to an embodiment of the present invention, the drug may optionally further include excipients;

[0025] Preferably, the auxiliary material comprises at least one of a stabilizer, a filler, a binder, a surfactant and a lubricant;

[0026] Preferably, the surfactant is selected from one or more of polyethylene glycol, sodium lauryl sulfate, Tween, and Span;

[0027] Preferably, the stabilizer is selected from one or both of carboxymethyl cellulose and mannitol;

[0028] Preferably, the filler is selected from one or more of lactose, mannitol, cyclodextrin, and sorbitol;

[0029] Preferably, the binder is selected from one or more of hydroxypropyl cellulose, methyl cellulose, sodium hyaluronate, collagen, and polyvinyl pyrrolidone;

[0030] Preferably, the lubricant is selected from one or more of magnesium stearate, calcium stearate, and stearic acid.

[0031] According to an embodiment of the present invention, the drug may optionally be further used in combination with other active ingredients, wherein the other active ingredients have the effect of promoting the growth of bone tissue and cartilage tissue;

[0032] Preferably, the other active ingredients are selected from one or more of collagen, gelatin, osteocalcin (Bone Gla Protein, BGP), bone morphogenetic protein (BMP), basic fibroblast growth factor (Basic Fibroblast Growth Factor, bFGF), insulin growth factor (Insulin Iike Growth Factor, IGF), transforming growth factor β (Transforming Growth Factor-β, TGF-β), platelet derived growth factor (Platelet derivedgrowth factor, PDGF), concentrated growth factor fibrin (Concentrated Growth Facter, CGF) and platelet-rich fibrin (Platelet-Rich Fibrin, PRF), etc.

[0033] According to an embodiment of the present invention, the administration method of the drug includes but is not limited to intravenous injection, in situ injection, intramuscular injection, subcutaneous injection, oral administration, topical application, etc.

[0034] According to an embodiment of the present invention, the dosage form of the drug is injection, tablet, granule, capsule, oral liquid, ointment, etc.; preferably injection.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] The present invention discovers for the first time that polylactic acid and its copolymers, polylactic acid microspheres, and polylactic acid copolymer microspheres have the function of promoting the growth of bone tissue and cartilage tissue, providing a new approach for promoting the growth of bone tissue and cartilage tissue. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of this application. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0038] FIG1 is a scanning electron microscope (SEM) image of poly (L-lactic acid) (PLLA) microspheres in Example 1.

[0039] FIG2 is a scanning electron microscope (SEM) image of poly(lactic acid-co-glycolic acid) (PLGA) microspheres in Example 2.

[0040] FIG3 is a graph showing the effect of PLLA microsphere solution on the proliferation behavior of osteoblasts.

[0041] FIG4 is a graph showing the effect of PLGA microsphere solution on the proliferation behavior of chondrocytes.

[0042] FIG5 is a test result of the relative expression levels of cartilage-related genes after in vitro culture of the PLGA microsphere solution-cell complex.

[0043] FIG6 is the immunohistochemical results of the effect of PLGA microsphere solution on cartilage tissue growth. DETAILED DESCRIPTION

[0044] The technical solutions of the present invention will be described in further detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are encompassed within the scope of protection that the present invention is intended to protect.

[0045] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0046] Example 1 Preparation and Characterization of L-Polylactic Acid Microspheres

[0047] 9 g of L-polylactic acid (PLLA) (molecular weight 15000 g / mol) was dissolved in 135 mL of dichloromethane, and then the above polymer solution was added to 1800 mL of a 0.5% polyvinyl alcohol aqueous solution. After emulsification at 3000 rpm / min for 10 minutes, the mixture was stirred at 500 rpm for 3 hours to remove the dichloromethane, and the L-polylactic acid microspheres were obtained after freeze-drying.

[0048] The prepared L-polylactic acid microspheres were observed by scanning electron microscopy and the particle size was calculated. The SEM image of the L-polylactic acid microspheres is shown in FIG1 . The particle size of the microspheres ranged from 3.72 to 33.12 μm.

[0049] Example 2 Preparation and Characterization of Poly(lactic-co-glycolic acid) Microspheres

[0050] 9 g of poly(lactic acid-co-glycolic acid) (PLGA) (molecular weight 15000 g / mol) was dissolved in 135 mL of dichloromethane, and then the polymer solution was added to 1800 mL of a 0.5% polyvinyl alcohol aqueous solution. After emulsification at 3000 rpm / min for 10 minutes, the mixture was stirred at 500 rpm for 3 hours to remove the dichloromethane, and the poly(lactic acid-co-glycolic acid) microspheres were obtained after freeze-drying.

[0051] The prepared poly(lactic acid-co-glycolic acid) microspheres were observed by scanning electron microscopy and the particle size was calculated. The scanning electron microscope (SEM) image of the PLGA microspheres is shown in FIG2 . The particle size of the microspheres ranged from 2.94 to 36.92 μm.

[0052] Example 3 Experiment on the effect of poly (L-lactic acid) (PLLA) microsphere solution on osteoblast proliferation

[0053] The MTT method was used to test the effect of the PLLA microsphere solution in Example 1 on the proliferation of mouse embryonic osteoblasts MC3T3.

[0054] PBS buffer was used as the blank control group, and PLLA microsphere solutions with mass concentrations of 10%, 20%, and 30% were prepared with PBS buffer as the experimental groups. First, the above samples were added to a 96-well plate, 100 μL per well, and 5 parallel wells were set for each sample. Then, 100 μL of 1×10 4 The cells were then suspended in a 100 μL / mL MC3T3 cell suspension and placed in a cell culture incubator. After incubation in the dark for 1, 3, 5, and 7 days, 20 μL of MTT solution was added to each well. After incubation in the dark for 4 hours, the supernatant was removed from each well and dissolved in 150 μL of dimethyl sulfoxide until a transparent solution was obtained. The readings at 570 nm were measured using a microplate reader, and the effects of different concentrations of PLLA microsphere solutions on MC3T3 cell proliferation were calculated.

[0055] The results are shown in Figure 3. Compared with the blank control group, different concentrations of PLLA microsphere solutions all promoted the proliferation of osteoblasts. Moreover, as the concentration of PLLA microspheres increased, the number of proliferating osteoblasts also gradually increased. This shows that the PLLA microsphere solution has a significant effect in promoting osteoblast proliferation.

[0056] Example 4 Experimental study on the effect of poly (L-lactic acid) PLLA microsphere solution on bone tissue growth

[0057] 1. Establishment of osteoporosis model:

[0058] Forty 3-month-old non-pregnant female SD rats weighing about 200 g were selected and underwent bilateral ovariectomy. The rats were then fed for 3 months.

[0059] 2. Implantation of microspheres and in vivo osteogenesis testing:

[0060] (1) Specimen preparation

[0061] After anesthesia, the rats were placed prone on the surgical panel. The bilateral greater trochanters of the femur were cut and exposed, and a bone defect of 2.5 mm in diameter and 3 mm in depth was made from the greater trochanter to the lesser trochanter using an electric drill. 40 castrated rats were randomly divided into 5 groups, with 8 rats in each group. They were: control group (sham operation), buffer group (PBS buffer was injected into the intertrochanteric bone defect area), low-concentration PLLA microsphere group (microspheres with a concentration of 5% / PBS buffer), medium-concentration PLLA microsphere group (microspheres with a concentration of 10% / PBS buffer), and high-concentration PLLA microsphere group (microspheres with a concentration of 20% / PBS buffer). 30 μL of the above sample was injected into the defects on both sides of the rats, and the muscles and skin were sutured in layers. Three months after the operation, the 8 rats in each group were killed, the intact femurs were removed, the soft tissues were cleaned, and they were wrapped with saline gauze and stored at -20°C. The PLLA microspheres used were prepared in Example 1.

[0062] (2) Measurement of bone density in the intertrochanteric region of the femur

[0063] Femoral specimens were scanned using an X-ray absorptiometry instrument to measure bone mineral content (BMC) and bone mineral density (BMD) in the intertrochanteric region. As shown in Table 1, 3 months after surgery, the BMC and BMD in the microsphere group were comparable to those in the control and buffer solution groups. Furthermore, as the microsphere concentration increased, the BMC and BMD values ​​gradually increased (both differences in the intertrochanteric region were statistically significant).

[0064] Table 1 Comparison of intertrochanteric bone mineral content and bone density of different samples 3 months after surgery (n=8)

[0065] (3) Micro CT observation of trabecular bone structure in the intertrochanteric region of the femur

[0066] Femora were dissected from the inferior margin of the lesser trochanter, and the proximal end was placed along its long axis in a sample container. Scanning was performed at 80 kV and a resolution of 6.8 μm to measure bone morphometric parameters in the intertrochanteric region. These parameters included: 1) percent trabecular area (%Tb.Ar): trabecular area as a percentage of bone tissue area, reflecting bone mass; 2) trabecular thickness (Tb.Th): describes the morphology of trabecular structure. Given a given amount of trabecular mass, greater thickness indicates greater bone mass; and 3) trabecular spacing (Tb.Sp): describes the average distance between trabeculae. Greater trabecular spacing indicates greater trabecular spacing and more porous bone.

[0067] As can be seen from the data in Table 2, 3 months after surgery, the trabecular bone thickness values ​​in the microsphere sample group were significantly higher than those in the control and buffer groups, and trabecular bone thickness gradually increased with increasing microsphere concentration (the differences between the groups were statistically significant). In addition, the trabecular bone area percentage in the 20% microsphere sample group was significantly higher than that in the control and buffer groups, but there was no statistically significant difference compared with the 5% and 10% microsphere groups. 3 months after surgery, the trabecular bone separation values ​​in the microsphere sample group were lower than those in the control and buffer groups, and trabecular bone separation gradually decreased with increasing microsphere concentration (the differences between the groups were statistically significant).

[0068] Table 2 Comparison of intertrochanteric trabecular histomorphology of different samples 3 months after surgery (n=8)

[0069] Example 5 Experimental study on the effect of poly(lactic-co-glycolic acid) PLGA microsphere solution on chondrocytes

[0070] 1. Chondrocyte Extraction and Culture

[0071] The chondrocytes are taken from the cartilage tissue of the ears of three-week-old New Zealand white rabbits and cultured and passaged once every one week or so. The present invention uses the third generation chondrocytes for the implantation of the microsphere material.

[0072] 2. MTT assay to test the effect of PLGA microsphere solution on chondrocyte proliferation

[0073] PBS buffer was used as the blank control group, and PLGA microsphere solutions with mass concentrations of 10%, 20%, and 40% were prepared with PBS buffer as the experimental groups. First, the samples of each group were added to a 96-well plate, with 100 μL of microsphere solution per well, and 5 parallel wells were set for each sample. Then, 100 μL of 1×10 4 After 2, 4, 6, and 8 days of incubation in the dark, 20 μL of MTT solution was added to each well. After 4 hours of incubation in the dark, the supernatant in each well was removed and then dissolved with 150 μL of dimethyl sulfoxide to a transparent solution. The reading at 570 nm was measured by a microplate reader, and the proliferation results of chondrocytes on microsphere samples of different concentrations were finally calculated. The polylactic acid-co-glycolic acid microspheres were prepared in Example 2.

[0074] The test results are shown in Figure 4. Compared with the blank control group, different concentrations of PLGA microsphere solutions can promote the proliferation of chondrocytes; and with the increase of culture time and microsphere concentration, the number of chondrocytes in the sample group also gradually increased, indicating that PLGA microspheres can promote the proliferation of chondrocytes.

[0075] Example 6 Effect of Poly(lactic-co-glycolic acid) PLGA Microsphere Solution on the Growth of Cartilage Tissue

[0076] 1. Isolation of Chondrocytes

[0077] Under sterile conditions, cut the pig auricle cartilage into pieces of about 2cm×2cm. After removing the skin and subcutaneous tissue, remove the perichondrium and cut into pieces of about 1mm in size. 3 Cartilage blocks were digested with 0.25% trypsin for 40 minutes, and then 5 times the volume of 0.2% collagenase was added and digestion continued for 16-24 hours. After filtering the cells with a cell strainer, the precipitate was collected by repeated centrifugation and finally cultured in a constant temperature incubator to obtain P0 pig ear chondrocytes.

[0078] 2. Mixing of Chondrocytes and PLGA Microspheres

[0079] PBS buffer was used to prepare PLGA microsphere solutions with a mass concentration of 10% and 40% as the experimental groups. P2 generation pig ear chondrocytes were selected with a density of 1×10 8 / mL cell suspension. Appropriate amounts of cell suspension, PLGA microsphere solution, and culture medium were added to a 6-well plate and cultured in a constant temperature incubator. Specific groupings are shown in Table 3.

[0080] Table 3 Specific composition information of group A and group B

[0081] 3. Real-time PCR

[0082] After the cell microspheres were cultured in vitro for 4 weeks, the expression of cartilage-related genes was detected by real-time PCR, and the expression levels of each group relative to the internal reference gene GAPDH were statistically analyzed.

[0083] 1) Reaction system: 0.3 μl of upstream and downstream primers, 5 μl of SYBR, 0.4 μl of template, and 4 μl of ddH2O.

[0084] 2) Reaction procedure: 95°C for 1 min, 95°C for 5 s, 60°C for 1 min, 40 cycles.

[0085] 3) Quantitative analysis was performed using GAPDH in each group as an internal reference.

[0086] 4) The primer sequences are shown in Table 4.

[0087] Table 4 Real-time PCR primer sequences

[0088] Figure 5 shows the relative expression of cartilage-related genes after in vitro culture of microsphere-chondrocyte complexes. The results show that PLGA microspheres promote cartilage formation. Compared with low-concentration microsphere samples, high-concentration microsphere samples showed significantly higher expression of cartilage-related genes, and the difference was statistically significant.

[0089] Example 7 Effect of Poly(lactic-co-glycolic acid) PLGA Microsphere Solution on Cartilage Tissue Growth

[0090] 1. In vivo injection of microsphere solution

[0091] Three healthy Bama miniature pigs, male, 2 months old, weighing 8-10 kg, were collected. After anesthesia and disinfection, subcutaneous cavities were isolated according to aseptic procedures. A PBS buffer solution served as a control group, while PLGA microsphere solutions prepared in PBS buffer at concentrations of 20% and 60% were used as sample groups. 1 mL of each solution was injected subcutaneously on both sides of the pig's back. The cavities were then sutured and marked. The samples were removed two weeks after injection and placed in formalin for histological staining.

[0092] 2. Histological Staining

[0093] (1) Tissue section preparation

[0094] 1) The tissue fixed with 10% formalin was trimmed into tissue blocks of appropriate size.

[0095] 2) Dehydration in graded ethanol: 70% ethanol for 30 minutes, 80% ethanol for 30 minutes, 90% ethanol for 30 minutes, 95% ethanol I for 30 minutes, 95% ethanol II for 30 minutes, anhydrous ethanol I for 40 minutes, anhydrous ethanol II for 40 minutes, anhydrous ethanol:xylene (1:1) for 40 minutes, and xylene for 8 minutes twice.

[0096] 3) After taking out from xylene, quickly put into paraffin wax: xylene (1:1) for 40 minutes, soft wax with a melting point of 50-52°C for 40 minutes, and hard wax with a melting point of 60-62°C for 40 minutes.

[0097] 4) Embed the tissue in hard wax and leave it at room temperature overnight.

[0098] 5) The slice thickness of the tissue slicer is 5-8 μm.

[0099] 6) Spread the slide in 45℃ distilled water.

[0100] 7) Bake the slices at 50℃ for 1.5-2 hours and set aside.

[0101] 3. Immunohistochemical staining of type II collagen

[0102] 1) After freezing the sections at room temperature for 1 hour, fix them with 4% paraformaldehyde for 15 minutes. Wash them in PBS three times for 3 minutes each.

[0103] 2) Perform antigen retrieval according to the pepsin antigen retrieval kit. Add hydrogen peroxide methanol solution and incubate at room temperature for 10 minutes. Wash with PBS three times, 3 minutes each time.

[0104] 3) Incubate with pepsin for 30 minutes, and wash three times with PBS, each time for 3 minutes.

[0105] 4) Follow the immunohistochemistry kit steps and block with 3% hydrogen peroxide solution at room temperature to block endogenous enzymes.

[0106] 5) Wash with PBS three times, 3 minutes each time.

[0107] 6) Nonspecific antigens were blocked with 10% goat serum for 10 minutes.

[0108] 7) Dilute the primary antibody with PBS according to the manufacturer's instructions, discard the goat serum, add the primary antibody, and incubate at 4°C overnight.

[0109] 8) Equilibrate at room temperature for 1-2 hours.

[0110] 9) Discard the primary antibody and wash with PBS three times, 3 minutes each time.

[0111] 10) Add secondary antibody and incubate at 37°C for 30 minutes.

[0112] 11) Wash with PBS three times, 3 minutes each time.

[0113] 12) Prepare DAB colorimetric solution according to the instructions. Add the solution dropwise under a microscope and stop color development when a positive result appears.

[0114] 13) Stain with hematoxylin for 2 minutes and wash with water.

[0115] 14) Soak in tap water for 10 minutes.

[0116] 15) Dehydrate in anhydrous ethanol for 5 minutes.

[0117] 16) Transparent the slides with xylene I for 5 minutes and xylene II for 5 minutes, then seal the slides with neutral gum.

[0118] The immunohistochemical results are shown in Figure 6. Two weeks after in vivo injection, the PLGA microsphere solution samples showed significant positive expression of type II collagen compared to the PBS buffer solution group. Statistical results showed that the high-concentration microsphere solution showed significantly higher expression of type II collagen than the low-concentration solution. These results demonstrate that the PLGA microsphere solution can promote cartilage growth.

[0119] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not limiting. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the purpose and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.

Claims

1. Application of polylactic acid and its copolymers, polylactic acid microspheres, and polylactic acid copolymer microspheres in the preparation of drugs for promoting the growth of bone tissue and cartilage tissue, wherein: The molecular weight of the polylactic acid and its copolymer is 400Da-300kDa; Preferably, the molecular weight of the polylactic acid and its copolymer is 5000Da-100kDa; for example, 5000Da-20kDa, 15000Da.

2. The use according to claim 1, characterized in that The polylactic acid includes L-polylactic acid, D-polylactic acid and racemic polylactic acid, and is preferably L-polylactic acid.

3. The use according to claim 1, characterized in that The polylactic acid copolymer includes one or more of polylactic acid-glycolic acid copolymer, polylactic acid-polyethylene glycol copolymer, polyethylene glycol-polylactic acid-glycolic acid copolymer, polylactic acid-chitosan copolymer, and lactide-caprolactone copolymer; Preferably, the polylactic acid copolymer is a polylactic acid-glycolic acid copolymer.

4. The use according to any one of claims 1 to 3, characterized in that: The preparation method of polylactic acid microspheres and polylactic acid copolymer microspheres comprises the following steps: 1) mixing polylactic acid or a polylactic acid copolymer and a solvent to obtain a polylactic acid solution or a polylactic acid copolymer solution; Preferably, the solvent is any one of dichloromethane, chloroform, ethyl acetate, acetone or toluene, or a mixture of any two or more thereof; 2) Mixing the polylactic acid solution or the polylactic acid copolymer solution with the polyvinyl alcohol aqueous solution, emulsifying at high speed, stirring to remove the solvent, and freeze-drying to obtain polylactic acid microspheres.

5. The use according to claim 4, characterized in that In step 1), the mass volume ratio of polylactic acid or polylactic acid copolymer to solvent is 1g:5mL-1g:30mL, preferably 1g:10mL-1g:20mL, for example 1g:15mL; and / or, in step 2), the mass concentration of the polyvinyl alcohol aqueous solution is 0.05%-5.0%, preferably 0.1%-2.0%, for example 0.5%; And / or, in step 2), the volume ratio of the polylactic acid solution or the polylactic acid copolymer solution to the polyvinyl alcohol aqueous solution is 1:5-1:30, preferably 1:10-1:20, for example 1:13, 1:15; And / or, in step 2), the rotation speed of the high-speed emulsification is 1000 rpm / min-5000 rpm / min, for example 3000 rpm / min; And / or, in step 2), the emulsification time is 5-20 minutes, for example 10 minutes.

6. The use according to any one of claims 1 to 5, characterized in that: When administered, the mass concentration of polylactic acid and its copolymers, polylactic acid microspheres, and polylactic acid copolymer microspheres is 1%-80%, preferably 5%-50%, such as 10%, 20%, 30%, 40%.

7. The use according to any one of claims 1 to 6, characterized in that: The drug may optionally further include excipients; Preferably, the auxiliary material includes at least one of a stabilizer, a filler, a binder, a surfactant and a lubricant; Preferably, the surfactant is selected from one or more of polyethylene glycol, sodium dodecyl sulfate, Tween, and Span; Preferably, the stabilizer is selected from one or both of carboxymethyl cellulose and mannitol; Preferably, the filler is selected from one or more of lactose, mannitol, cyclodextrin, and sorbitol; Preferably, the binder is selected from one or more of hydroxypropyl cellulose, methyl cellulose, sodium hyaluronate, collagen, and polyvinyl pyrrolidone; Preferably, the lubricant is selected from one or more of magnesium stearate, calcium stearate and stearic acid.

8. The use according to any one of claims 1 to 7, characterized in that: The drug may optionally be further used in combination with other active ingredients, which have the effect of promoting the growth of bone tissue and cartilage tissue; Preferably, the other active ingredients are selected from one or more of collagen, gelatin, osteocalcin (Bone Gla Protein, BGP), bone morphogenetic protein (Bonemorphogenetic protein, BMP), basic fibroblast growth factor (Basic Fibroblast Growth Factor, bFGF), insulin growth factor (Insulin Iike Growth Factor, IGF), transforming growth factor β (Transforming Growth Factor-β, TGF-β), platelet derived growth factor (Platelet derivedgrowth factor, PDGF), concentrated growth factor fibrin (Concentrated Growth Facter, CGF) and platelet-rich fibrin (Platelet-Rich Fibrin, PRF), etc.

9. The use according to any one of claims 1 to 8, characterized in that: The administration methods of the drug include but are not limited to intravenous injection, in situ injection, intramuscular injection, subcutaneous injection, oral administration, application, etc.

10. The use according to any one of claims 1 to 8, characterized in that: The dosage form of the drug is injection, tablet, granule, capsule, oral liquid, ointment, etc.; preferably injection.